Triple Helix Science Evidence Atlas

Clinical trials

AtlasDatabaseBiomarkersHealthspan modelLive dataAbout

Ledger last scanned 2026-09

Registry feed — auto-updating

Last updated: never

Status, phase, enrollment and dates refresh automatically from ClinicalTrials.gov for every tracked intervention. Curated editorial notes — including trials that failed or returned null results — stay attached to their study record. Studies without a curated note are shown but marked pending review.

Loading registry snapshot…

    No registry record

    Curated programmes with no ClinicalTrials.gov entry. They stay listed — an absent registry record is itself evidence about the state of a programme.

    • Novartis / resTORbio · Phase I/IINO REGISTRY RECORD

      Rapamycin for Immune Senescence and Aging

      Tested mTOR inhibition for improving immune function in elderly. Phase 3 PROTECTOR trials did not meet endpoints.

    • Intervene Immune · Phase IINO REGISTRY RECORD

      TRIIM-X (Thymus Regeneration)

      Follow-up to TRIIM trial that demonstrated thymus regeneration and epigenetic age reversal.

    • Altos Labs · Preclinical/Phase INO REGISTRY RECORD

      Altos Labs — Cellular Reprogramming Program

      Backed by $3B in funding, Altos Labs is advancing partial cellular reprogramming using Yamanaka factors to reverse aging at the cellular level. Partnership with Stanford, UC Berkeley, and Cambridge.

    • Retro Biosciences · PreclinicalNO REGISTRY RECORD

      Retro Biosciences — Longevity Platform

      Sam Altman-backed $180M venture pursuing three parallel longevity approaches. University-industry collaboration with UCSF and Stanford.

    • Calico Labs (Alphabet) · Phase I/IINO REGISTRY RECORD

      Calico Labs — Aging Interventions Portfolio

      Alphabet's longevity company with $2.5B in funding. Partners with AbbVie on aging drug development. Partnership with Broad Institute and MIT.

    • Turn Biotechnologies · PreclinicalNO REGISTRY RECORD

      Turn Biotechnologies — ERA Platform

      Developing mRNA-based epigenetic reprogramming targeting specific tissues. Stanford-derived technology with government grants from NIA.

    • Rejuvenate Bio · Preclinical/Phase INO REGISTRY RECORD

      Rejuvenate Bio — Gene Therapy for Aging

      Harvard-spun-out company developing multi-gene therapy for aging reversal. Demonstrated lifespan extension in aged mice. NIH SBIR grants support translational work.

    • Loyal for Dogs · Phase II/IIINO REGISTRY RECORD

      Loyal — Large Dog Longevity Trial (LOY-002)

      FDA conditional approval pathway for first anti-aging drug. Testing in large breed dogs as translational model. University of Washington partnership.

    • Cambrian Bio · Phase INO REGISTRY RECORD

      Cambrian Bio — Aging Drug Pipeline

      Portfolio approach to aging with 15+ spinout companies. Deep ties to Harvard, MIT, and Mayo Clinic. Government-supported through ARPA-H initiatives.